Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Cancer|August 23, 2008
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemiaAzra Raza, Murtaza Mehdi, Muhammad Mumtaz, et al.Journal of Hematology & Oncology|April 27, 2010
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposureFahd Quddus, Jessica Clima, Helen Seedham, et al.Cancer Causes & Control : CCC|February 3, 2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromesXiaomei Ma, Rong Wang, Naomi Galili, et al.Seminars in Hematology|June 11, 2004
Targeted therapies in myelodysplastic syndromes: ASH 2003 reviewAnna Candoni, Federico Silvestri, Silvia Buonamici, et al.Leukemia & Lymphoma|January 7, 2006
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromesAzra Raza, Laurie Lisak, Jennifer Billmeier, et al.Journal of Hematology & Oncology|May 8, 2012
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndromeNaomi Galili, Pablo Tamayo, Olga B Botvinnik, et al.Leukemia Research|October 27, 2006
Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10Naomi Galili, Eric V Sechman, Jan Cerny, et al.International Journal of Hematology|October 16, 2004
Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrowGurveen Saberwal, Steven Lucas, Imke Janssen, et al.Leukemia Research|November 12, 2010
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromesRong Wang, Cary P Gross, Ronald J Maggiore, et al.Leukemia Research|September 25, 2007
Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcomeGang Yue, Suyang Hao, Oluwole Fadare, et al.Pageof 5